Opendata, web and dolomites

GRANROSE SIGNED

Using a blood cell-based approach to determine gluten responsiveness and to bring a novel, less invasive assay on the market to diagnose celiac disease.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "GRANROSE" data sheet

The following table provides information about the project.

Coordinator
MICROBIOME LIMITED 

Organization address
address: SIDNEY STREET 80
city: FOLKESTONE
postcode: CT19 6HQ
website: www.microbiome.eu

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 130˙062 €
 EC max contribution 130˙062 € (100%)
 Programme 1. H2020-EU.2.3.2.2. (Enhancing the innovation capacity of SMEs)
 Code Call H2020-INNOSUP-2019-02
 Funding Scheme CSA
 Starting year 2019
 Duration (year-month-day) from 2019-10-15   to  2020-10-14

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MICROBIOME LIMITED UK (FOLKESTONE) coordinator 130˙062.00

Map

 Project objective

Microbiome is a Dutch R&D-performing SME developing molecular diagnostic assays based on human biomarkers with one of its focuses to celiac disease diagnostics. We developed a molecular diagnostic assay to screen HLA genotypes that are known to be associated with celiac disease (CD). Up to date, CD is diagnosed by serology (e.g. the presence of auto-antibodies to tissue transglutaminase 2 in the serum) and diagnosis requires further proof by analysis of a duodenal biopsy specimen. The collection of biopsy specimens requires an invasive examination and correct embedding of the tissue is essential for proper analysis of the tissue. This part of CD diagnosis is expensive, elaborate and prone to mistake. Innovation that trustworthy and efficiently can replace biopsy is in high demand. GRANROSE will enable Microbiome to strengthen its position as an innovative biotech SME, developing a novel assay, NeutroScan, for the CD market. GRANROSE will do this through hiring an Innovation Associate (IA). • The IA will confirm and complete a biomarker panel that plays a role in gluten-related neutrophil function. • The IA will develop an assay to study neutrophil function in gluten-related disease. • The IA will perform a technical feasibility study for and investigate the market potential of the NeutroScan, an assay distinguishing gluten-related disease based on neutrophil function. GRANROSE will not only bring major benefits for Microbiome, but is focused around the training of the Innovation Associate, thereby greatly improving his/her career development. • Gaining novel technical skills and building an own research line with translational diagnostic applications. • Gaining innovation and business management skills in a multidisciplinary setting. • A training program tailored to his/her specific needs and major contribution to personal career development.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GRANROSE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GRANROSE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.2.2.)

PROBIM (2020)

PRO Business Innovation Moldova

Read More  

bsnEA (2020)

Business Support Network – East Anatolia

Read More  

DCS-iSMEs (2019)

Design Customized Support for Innovative SMEs

Read More